Showing results (821-830 of 1,120) with videos related to

Sort By:
Pageof 112
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 23, 2025
Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent ClaudicationKaren Falcão Britto, Roberto Augusto Caffaro, Giuliano Giova Volpiani, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|August 31, 2025
Cost-effectiveness of Apixaban vs Aspirin for the Reduction of Thrombo-Embolism in High-Risk Patients with Device-Detected Atrial Fibrillation: Insights from the ARTESiA trialAndre Lamy, Roopinder K Sandhu, Wesley Tong, et al.
Journal of Thrombosis and Thrombolysis|March 27, 2009
Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, BrazilRenato D Lopes, Richard C Becker, David Garcia, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Chronic Kidney DiseaseDeepak L Bhatt, Michael Szarek, Bertram Pitt, et al.
Circulation|November 6, 2022
Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled TrialSean D Pokorney, Glenn M Chertow, Hussein R Al-Khalidi, et al.
Journal of Inorganic Biochemistry|September 15, 2022
Preparation, cytotoxic activity and DNA interaction studies of new platinum(II) complexes with 1,10-phenanthroline and 5-alkyl-1,3,4-oxadiazol-2(3H)-thione derivativesWesley A Souza, Luana M S Ramos, Angelina M de Almeida, et al.
Journal of the American College of Cardiology|May 9, 2020
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES TrialDeepak L Bhatt, Andrew H Briggs, Shelby D Reed, et al.
Pageof 112